SS
TTNP

SBI Securities’s Titan Pharmaceuticals TTNP Stock Holding History

SBI Securities’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1
Closed -$5 – 4228
2025
Q3 		$5 Hold
1
– – ﹤0.01% 4109
2025
Q2 		$4 Hold
1
– – ﹤0.01% 4085
2025
Q1 		$4 Hold
1
– – ﹤0.01% 4053
2024
Q4 		$3 Buy
+1
New +$4 ﹤0.01% 4045

Other funds holding TTNP

CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
GWSA
Global Wealth Strategies & Associates Denver, Colorado $528M AUM 23.18% 1-Year Est. Return
CSC
Caldwell Sutter Capital Sausalito, California $246M AUM 23.62% 1-Year Est. Return
DJSG
D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

SBI Securities's TTNP Position: Q4 2025 in Review

SBI Securities sold out of Titan Pharmaceuticals (TTNP) in Q4 2025, closing a stake of 1 share — an estimated $5 sold.

SBI Securities first reported a position in TTNP in Q4 2024 and held it in 4 quarters. The position peaked at $5 in Q3 2025. 4 funds tracked by Wall St. Rank hold TTNP as of Q4 2025.

  • SBI Securities reported no remaining Titan Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • SBI Securities sold 1 Titan Pharmaceuticals share in Q4 2025, an estimated $5.
  • SBI Securities first reported a position in Titan Pharmaceuticals in Q4 2024 and held it in 4 quarters.
  • SBI Securities's Titan Pharmaceuticals position peaked at $5 in Q3 2025.
  • 4 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q4 2025.

Based on SBI Securities's 13F filing for Q4 2025, filed 3 Feb 2026.